Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Azabicycloalkanes: Synthesis and Applications

Project description

Exploring a new chemical space

Drug discovery usually involves the identification of active substances from natural sources or the rational synthesis of bioactive compounds through combinatorial chemistry. Modification or development of new synthetic methods is an ongoing effort to provide as many solutions as possible to the medicinal chemistry community. The EU-funded ABASynth project focuses on azabicyclic amines predicted to have great applicability considering the ubiquity of amines in bioactive organic molecules. Researchers will employ various chemical approaches to deliver novel functionalisation and molecular properties to azabicycloalkanes. The work is expected to introduce new chemical substituents of biologically relevant heterocycles with a variety of applications.

Objective

Small ring azabicyclic amines are predicted to possess unique molecular properties, but lack of synthetic access has to date prevented their thorough evaluation and deployment in high value functional molecules, including drugs. Much recent attention has focused on small-ring carbocyclic frameworks such as bicyclo[1.1.1]pentanes (BCPs), but analogous azabicyclic compounds are poorly described in the literature, which is surprising given the ubiquity of amines in bioactive organic molecules. A literature screen reveals that azabicyclo[2.2.1]heptanes are equivalent to BCPs in frequency of occurrence, but their [3.1.1] isomers and smaller azabicyclo[2.1.1]hexane relatives are much rarer. Azabicyclo[1.1.1]pentanes are essentially unknown, despite one isomer being an attractive bioisostere of the pyridine ring system. This proposal aims to address this ‘void’ in the bioisostere portfolio by introducing ‘small-ring azabicyloalkanes’ (ABAs) as novel motifs of great potential in drug discovery. As well as representing new bioisosteres for biologically-relevant heterocycles (not limited to pyridines, but also piperidines, pyrrolidines, etc.), ABAs offer new opportunities for drug design in their own right due to the impact of the bicyclic scaffold on amine hybridization. This project will deliver general access to small ring ABAs using a wide variety of novel chemical approaches, explore their functionalization, and demonstrate their application. It will use rational theoretical design to tailor ABA properties and develop structural models. Ultimately, this proposal will access a new domain of chemical space with broad application in organic and medicinal chemistry.

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Net EU contribution
€ 212 933,76
Address
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
United Kingdom

See on map

Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 212 933,76